ENGN

Business Context and Reporting Period

Company: enGene Therapeutics Inc. (ENGN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended April 30, 2026
Business Overview: enGene is a clinical-stage biotechnology company developing non-viral genetic medicines for mucosal tissues. Its lead product candidate, detalimogene voraplasmid, is in a pivotal Phase 2 trial (LEGEND) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The company operates as a single segment and has not yet generated revenue.

Key Financial Metrics

Note: Total liquid assets calculated as Cash ($29,827) + Short-term Marketable Securities ($228,638) + Long-term Marketable Securities ($26,709).

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $9.5 million year-over-year, driven by higher operating expenses.
• Expense Growth: R&D expenses rose $4.3 million due to increased personnel costs and clinical operations for the LEGEND trial. G&A expenses increased $5.1 million, primarily due to personnel hiring and facility costs.
• Capital Raise: The company raised approximately $140.1 million in net proceeds from a public offering of common shares and pre-funded warrants in November 2025, significantly boosting liquidity compared to the prior period.
• Debt Restructuring: In January 2026, the company entered a Second Amended Loan Agreement with Hercules Capital, increasing the facility to $125 million and extending the maturity to 2030. This resulted in a $0.5 million loss on extinguishment of debt.
• Share Count: Outstanding common shares increased from ~52 million to ~67 million due to the public offering.

Guidance, Outlook, and Risks

• Clinical Outlook: The company expects to initiate a Biologics License Application (BLA) submission in the second half of 2026 following FDA engagement. Enrollment in the pivotal LEGEND Cohort 1 is complete (125 patients). A new cohort incorporating a surfactant bladder rinse has begun enrollment.
• Strategic Restructuring (Subsequent Event): On June 15, 2026, the company announced a workforce reduction of approximately 50% to preserve cash. Estimated restructuring costs are $5.7–$6.4 million (cash) plus $4.7–$5.0 million in non-cash stock-based compensation.
• Liquidity: Management expects existing cash and marketable securities ($285.2 million as of April 30, 2026) to fund operations for at least 12 months. The company retains access to up to $100 million under its debt facility and $100 million under an At-The-Market (ATM) sales agreement.
• Key Risks: Dependence on the success of detalimogene; uncertainty regarding FDA approval timelines; need for additional funding to support commercialization; and execution risks associated with the recent workforce reduction and leadership changes (resignation of CMO).

Investor Verification Checklist

• Runway Validation: Verify if the 50% workforce reduction and associated cost savings are sufficient to extend the cash runway beyond the stated 12-month period without further dilution.
• BLA Timeline: Monitor the outcome of the pre-BLA meeting with the FDA scheduled for late 2026 and the acceptance of the BLA filing.
• Debt Covenants: Confirm continued compliance with the financial covenant requiring a minimum of $10 million in unrestricted cash under the Hercules loan agreement.
• Leadership Stability: Assess the impact of the CMO resignation and the appointment of an interim CMO on clinical trial execution and regulatory strategy.
• Restructuring Costs: Track the actual recognition of the estimated $10–11 million in restructuring charges in the second half of 2026.